Efficacy and safety of eslicarbazepine acetate (BIA 2-093) as adjunctive therapy for refractory partial seizures in children a doublie-blind, randomised, placebo-controlled, parallel-group, multicentre clinical trial.

Trial Profile

Efficacy and safety of eslicarbazepine acetate (BIA 2-093) as adjunctive therapy for refractory partial seizures in children a doublie-blind, randomised, placebo-controlled, parallel-group, multicentre clinical trial.

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 28 Apr 2017

At a glance

  • Drugs Eslicarbazepine acetate (Primary)
  • Indications Partial epilepsies
  • Focus Registrational; Therapeutic Use
  • Sponsors Bial
  • Most Recent Events

    • 28 Apr 2017 Results of population pharmacokinetics modeling of this and one other trial presented at the 69th Annual Meeting of the American Academy of Neurology.
    • 18 Dec 2016 According to a Bial media release, based on the data from this study, one phase II study (profile 700204098) and from population PK modelling and exposure-efficacy analyses, the European Commission has extended the marketing authorisation for eslicarbazepine acetate as a once-daily adjunctive treatment for patients aged above six years with partial-onset (focal) seizures with or without secondary generalisation.
    • 10 Aug 2015 Planned End Date changed from 1 Oct 2015 to 1 Jun 2017 as reported by ClinicalTrials.gov
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top